1. Doughari HJ, Ndakidemi PA, Human IS, Benade S. The ecology, biology and pathogenesis of Acinetobacter spp.: an overview. Microbes Environ. 2011;26(2):101-12.
2. Munoz-Price LS, Weinstein RA. Acinetobacter infection. N Engl J Med. 2008 Mar 20;358(12):1271-81.
3. Jung J, Park W. Acinetobacter species as model microorganisms in environmental microbiology: current state and perspectives. Appl Microbiol Biotechnol. 2015 Mar;99(6):2533-48.
4. https://www.gbif.org/species/3223263
5. De Rosa FG, Corcione S, Pagani N, Di Perri G. From ESKAPE to ESCAPE, from KPC to CCC. Clin Infect Dis. 2015;60(8):1289. Epub 2014 Dec 23.
6. WHO. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. World Health Organization, Geneva, Switzerland; 2017.
7. Juni E. Interspecies transformation of Acinetobacter: genetic evidence for a ubiquitous genus. J Bacteriol. 1972;112(2):917.
8. Garnacho-Montero J, Amaya-Villar R. Multiresistant Acinetobacter baumannii infections: epidemiology and management. Curr Opin Infect Dis 2010; 23:332.
9. Chuang YC, Sheng WH, Li SY, et al. Influence of genospecies of Acinetobacter baumannii complex on clinical outcomes of patients with acinetobacter bacteremia. Clin Infect Dis 2011; 52:352.
10. Lucidi M, Visaggio D, Migliaccio A, et al. Pathogenicity and virulence of Acinetobacter baumannii: Factors contributing to the fitness in healthcare settings and the infected host. Virulence,
2024; 15:1, 2289769
11. Hung YT, Lee YT, Huang LJ, et al. Clinical characteristics of patients with Acinetobacter junii infection. J Microbiol Immunol Infect 2009; 42:47
12. Leung WS, Chu CM, Tsang KY, et al. Fulminant community-acquired Acinetobacter baumannii pneumonia as a distinct clinical syndrome. Chest 2006; 129:102.
13. Eveillard M, Kempf M, Belmonte O, et al. Reservoirs of Acinetobacter baumannii outside the hospital and potential involvement in emerging human community-acquired infections. Int J
Infect Dis 2013; 17:e802.
14. Richards AM, Abu Kwaik Y, Lamont RJ. Code blue: Acinetobacter baumannii, a nosocomial pathogen with a role in the oral cavity. Mol Oral Microbiol 2015; 30:2.
15. Weiner LM, Webb AK, Limbago B, et al. Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety
Network at the Centers for Disease Control and Prevention, 2011-2014. Infect Control Hosp Epidemiol 2016; 37:1288.
16. Castillo-Ramírez S, Aguilar-Vera A, Kumar A, Evans B. Acinetobacter baumannii: much more than a human pathogen. Antimicrob Agents Chemother. 2025 Sep 3;69(9):e0080125.
17. Oncül O, Keskin O, Acar HV, Küçükardali Y, Evrenkaya R, Atasoyu EM, Top C, Nalbant S, Ozkan S, Emekdaş G, Cavuşlu S, Us MH, Pahsa A, Gökben M. Hospital-acquired infections fol-
lowing the 1999 Marmara earthquake. J Hosp Infect. 2002 May;51(1):47-51.
18. Karen C. Carroll, Michael A. Pfaller, James Karlowsky, et al. Manual of Clinical Microbiology, e-book, 2023: 911-943
19. Boll JM, Tucker AT, Klein DR, et al. Reinforcing lipid A acylation on the cell surface of Acinetobacter baumannii promotes cationic antimicrobial peptide resistance and desiccation survival.
MBio. 2015;6(3): e00478–15.
20. Pakharukova N, Tuittila M, Paavilainen S, et al. Structural basis for Acinetobacter baumannii biofilm formation. Proc Natl Acad Sci, USA. 2018;115 (21):5558–5563.
21. Harding CM, Hennon SW, Feldman MF. Uncovering the mechanisms of Acinetobacter baumannii virulence. Nat Rev Microbiol. 2018;16(2):91–102.
22. Lee JS, Choi CH, Kim JW, et al. Acinetobacter baumannii outer membrane protein a induces dendritic cell death through mitochondrial targeting. J Microbiol. 2010;48(3):387–392.
23. Sánchez-Encinales V, Álvarez-Marín R, Pachón-Ibáñez ME, et al. Overproduction of outer membrane protein a by Acinetobacter baumannii as a risk factor for nosocomial pneumonia,
bacteremia, and mortality rate increase. J Infect Dis. 2017;215(6):966–974.
24. Ren X, Palmer LD, Ottemann KM. Acinetobacter Metabolism in Infection and Antimicrobial Resistance. Infect Immun. 2023;91(6):e0043322
25. Wong, D., Nielsen, T. B., Bonomo, R. A., Pantapalangkoor, P., Luna, B., and Spellberg, B. Clinical and pathophysiological overview of Acinetobacter infections: a century of challenges. Clin
Microbiol Rev. 2017; 30, 409–447.
26. Cavallo I, Oliva A, Pages R, Sivori F, Truglio M, Fabrizio G, Pasqua M, Pimpinelli F and Di Domenico EG. Acinetobacter baumannii in the critically ill: complex infections get complicated.
Front. Microbiol. 2023; 14:1196774
27. Patel, A., Emerick, M., Cabunoc, M. K., Williams, M. H., Preas, M. A., Schrank, G., et al. Rapid spread and control of multidrug-resistant gram-negative bacteria in COVID-19 patient care
units. Emerg. Infect. Dis. 2021; 27, 1234–1237.
28. Russo, A., Gavaruzzi, F., Ceccarelli, G., Borrazzo, C., Oliva, A., Alessandri, F., et al. Multidrug-resistant Acinetobacter baumannii infections in COVID-19 patients hospitalized in intensive care
unit. Infection 2022; 50, 83–92.
29. Boutzoukas A, Doi Y. The global epidemiology of carbapenem-resistant Acinetobacter baumannii. JAC Antimicrob Resist. 2025 Jul 29;7(4): dlaf134.
30. Centers for Disease Control and Prevention. Antimicrobial Resistance & Patient Safety Portal. Carbapenem-resistant Acinetobacter baumannii (CRAB): An urgent public health threat in
United States healthcare facilities. 2021; Available at: https: / /arpsp.cdc.gov/story/cra-urgent-public-health-threat
31. Tsimogianni A, Alexandropoulos P, Chantziara V, Vassi A, Micha G, Lagiou F, Chinou E, Michaloudis G, Georgiou S. Intrathecal or intraventricular administration of colistin, vancomycin
and amikacin for central nervous system infections in neurosurgical patients in an intensive care unit. Int J Antimicrob Agents. 2017 Mar;49(3):389-390.
32. Granata G, Petersen E, Capone A, et al. The impact of armed conflict on the development and global spread of antibiotic resistance: a systematic review. Clin Microb Infect, 30 (7):858 – 865
33. Marí-Almirall, M.; Cosgaya, C.; Higgins, P.G.; Van Assche, A.; Telli, M.; Huys, G.; Lievens, B.; Seifert, H.; Dijkshoorn, L.; Roca, I.; et al. MALDI-TOF/MS Identification of Species from the Aci-
netobacter baumannii (Ab) Group Revisited: Inclusion of the Novel A. Seifertii and A. Dijkshoorniae Species. Clin. Microbiol. Infect. 2017, 23, 210.e1–210.e9
34. http://www.ncbi.nlm.nih.gov/bioproject/183623
35. Sharma, A.; Gaind, R. Development of Loop-Mediated Isothermal Amplification Assay for Detection of Clinically Significant Members of Acinetobacter calcoaceticus–Baumannii Complex
and Associated Carbapenem Resistance. Front. Mol. Biosci. 2021, 8, 659256
36. Lodise TP, Nguyen ST, Margiotta C, Cai B. Clinical burden of Acinetobacter baumannii, including carbapenem-resistant A. baumannii, in hospitalized adult patients in the USA between 2018
and 2022. BMC Infect Dis. 2025 Apr 17;25(1): 549.
37. Seifert H, Blondeau J, Lucaßen K, Utt E. Global update on the in vitro activity of tigecycline and comparators against isolates of Acinetobacter baumannii and rates of resistant phenotypes
(2016–2018). J Glob Antimicrob Resist 2022; 31: 82–9.
38. European Centre for Disease Prevention and Control. WHO Regional Office for Europe/European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe
2022–2020 data; 2022. Available at: https://www. ecdc.europa.eu/en/publications-data/antimicrobial-resistance-surveillance-europe- 2022-2020-data.
39. Ulusal Antimikrobiyal Direnç Sürveyans (UAMDS) Ağı 2022-2023 Yıllık Raporu. T.C. Sağlık Bakanlığı, Halk Sağlığı Genel Müdürlüğü 2024. https://hsgm.saglik.gov.tr/tr/surveyanslar/uam-
dss.html
40. Kubin CJ, Garzia C, Uhlemann A-C. Acinetobacter baumannii treatment strategies: a review of therapeutic challenges and considerations. Antimicrob Agents Chemother. 2025 Aug
6;69(8):e0106324.
41. Castanheira M, Mendes RE, Gales AC. Global Epidemiology and Mechanisms of Resistance of Acinetobacter baumannii-calcoaceticus Complex. Clin Infect Dis. 2023 May 1;76(Suppl 2):
S166-S178.
42. Wu HJ, Xiao ZG, Lv XJ, et al. Drug-resistant Acinetobacter baumannii: from molecular mechanisms to potential therapeutics (Review). Exp Ther Med 2023, 25:209.
43. Boral B, Unaldi Ö, Ergin A, Durmaz R, Eser ÖK; Acinetobacter Study Group. A prospective multicenter study on the evaluation of antimicrobial resistance and molecular epidemiology of
multidrug-re sistant Acinetobacter baumannii infections in intensive care units with clinical and environmental features. Ann Clin Microbiol Antimicrob 2019; 18:19.
44. Kaye KS, Shorr AF, Wunderink RG, et al. Efficacy and safety of sulbactam–durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter bauman-
nii–calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK). The Lancet Infectious Diseases, 2023; 3 (9): 1072-1084.
45. Kollef M, Dupont H, Greenberg DE, Viale P, Echols R, Yamano Y, Nicolau DP. Prospective role of cefiderocol in the management of carbapenem-resistant Acinetobacter baumannii infections:
Review of the evidence. Int J Antimicrob Agents. 2023 Aug;62(2): 106882.
46. Karakonstantis S, Ioannou P, Samonis G et al. Systematic review of antimicrobial combination options for pan-drug-resistant Acinetobacter baumannii. Antibiotics (Basel) 2021; 10:1344.
47. Huang C, Chen I, Tang T. Colistin monotherapy versus colistin plus meropenem combination therapy for the treatment of multidrug-resistant Acinetobacter baumannii infection: a metaa-
nalysis. J Clin Med 2022; 11:3239.
48. Hong DJ, Kim JO, Lee H et al. In vitro antimicrobial synergy of colistin with rifampicin and carbapenems against colistin-resistant Acinetobacter baumannii clinical isolates. Diagn Microbiol
Infect Dis 2016; 86:184–9.
49. Ergonul O, Tokca G, Keske Ş, Donmez E, Madran B, Kömür A, Gönen M, Can F. Elimination of healthcare-associated Acinetobacter baumannii infection in a highly endemic region. Int J
Infect Dis. 2022 Jan; 114:11-14